ARCA and Medtronic, Inc. (NYSE: MDT) have entered into a collaboration agreement to support the Phase 2B portion of GENETIC-AF, ARCA’s Phase 2B/3 clinical trial evaluating Gencaro as a potential treatment for atrial fibrillation. Medtronic is a leader in medical technologies to improve the treatment of chronic diseases, including cardiac rhythm disorders. www.medtronic.com
ARCA’s founding scientists are affiliated with the University of Colorado, and important biotechnology that is under development by ARCA had its origins in University Laboratories. ARCA is proud of its longstanding partnership and licensing agreement with the University.